What are the anesthesia risks associated with glucagon‑like peptide‑1 (GLP‑1) receptor agonists (e.g., exenatide, liraglutide, semaglutide, dulaglutide) and how should they be managed perioperatively?

GLP-1 Receptor Agonists Increase Anesthesia Risk Through Delayed Gastric Emptying and Potential Pulmonary Aspiration

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide) significantly delay gastric emptying and increase the risk of retained gastric contents during anesthesia, even after standard fasting, requiring specific perioperative management strategies to prevent pulmonary aspiration. 1, 2

Primary Risk: Pulmonary Aspiration

The core anesthesia concern is delayed gastric emptying leading to retained gastric contents and potential aspiration during induction or emergence from anesthesia. The FDA explicitly warns that GLP-1 RAs delay gastric emptying, and postmarketing reports document pulmonary aspiration in patients undergoing elective procedures despite adherence to standard fasting 2. The European Medicines Agency Pharmacovigilance Risk Assessment Committee has highlighted this risk 1.

Evidence of increased risk:

• Studies show an OR of 10.23 (95%CI 2.94-35.82) for pulmonary aspiration in elective surgery 1
• Endoscopy studies found 24.2% of semaglutide patients had increased residual gastric content vs. 5.1% controls (p=0.001) despite 10-14 day drug cessation and extended fasting 3
• Multiple case reports document aspiration requiring ICU admission despite fasting periods of 10-20 hours 3

Perioperative Management Algorithm

Pre-Procedure Assessment (Document These Specifics):

• Drug details: Exact agent, dose, frequency (daily vs weekly), date started, last dose taken
• GI symptoms: Active nausea, vomiting, abdominal distention, early satiety
• Treatment phase: Recently initiated (<12 weeks) or dose escalation increases risk
• Indication: Weight loss vs diabetes (weight loss typically uses higher doses)
• Concomitant factors: Opioids, gastroparesis, prior GI surgery, alcohol/cannabis use 3

Drug Cessation Strategy:

For patients using GLP-1 RAs for weight loss: Hold for at least 3 half-lives before elective procedures 3:

• Semaglutide (weekly): 21 days (3 × 7-day half-life)
• Dulaglutide (weekly): 13-14 days (3 × 4.5-day half-life)
• Tirzepatide (weekly): 15 days (3 × 5-day half-life)
• Liraglutide (daily): 1.5 days (3 × 13-hour half-life) 1

For patients with diabetes mellitus: Consult endocrinology regarding risks/benefits of 3 half-life cessation vs. continuing therapy, as these drugs provide cardiovascular protection and glycemic control 1, 3. The 2025 multidisciplinary consensus acknowledges conflicting priorities between aspiration risk and metabolic benefits 1.

High-Risk Patient Identification:

Patients at elevated aspiration risk requiring enhanced precautions 3:

• Unable to hold drug for 3 half-lives
• Recently started medication or dose escalation
• Active GI symptoms (nausea, vomiting, bloating)
• Morbid obesity
• Emergency/urgent surgery

Day-of-Surgery Risk Mitigation:

If drug held for 3 half-lives AND patient asymptomatic: Proceed with standard anesthetic approach 3

If high-risk features present 3:

1. Consider gastric ultrasound to assess residual volume (>1.5 ml/kg or solid contents = high risk)

2. Pharmacologic interventions:

   • Prokinetic agents (metoclopramide or erythromycin) pre-operatively
   • Consider pre-emptive gastric decompression in very high-risk cases

3. Anesthetic modifications:

   • Rapid sequence intubation with cricoid pressure
   • Avoid supraglottic airways in high-risk patients
   • Regional anesthesia when feasible
   • Maintain full-stomach precautions throughout

4. Dietary modification: Clear liquid diet 24-48 hours pre-procedure for symptomatic patients 3

Critical Caveats

Standard fasting is insufficient: Multiple case reports document aspiration despite 10-20 hour fasts 3. Even 10-14 day drug cessation did not normalize gastric emptying in some studies 3.

Tachyphylaxis uncertainty: While some suggest gastric effects diminish after 12+ weeks of chronic therapy, studies show patients on long-acting GLP-1 RAs for median 57 months still had significantly increased gastric residue 3. Do not assume chronic users are protected.

Weekly formulations are highest risk: Semaglutide, dulaglutide, and tirzepatide have prolonged half-lives (4.5-7 days) making adequate washout periods impractical for urgent procedures 1.

Aspiration can occur at emergence: Two documented cases involved regurgitation during supraglottic airway removal or extubation 3, requiring vigilance throughout the perioperative period.

Additional Anesthesia Considerations

• Hypoglycemia risk: When combined with insulin or sulfonylureas, particularly if GLP-1 RA continued perioperatively 2
• Cardiovascular effects: Mean heart rate increase of 2-3 bpm; monitor in cardiac patients 2
• Oral medication absorption: Delayed gastric emptying may affect absorption of other perioperative oral medications 2

The 2025 multidisciplinary consensus 1 represents the most current guidance, emphasizing individualized risk assessment over blanket cessation policies, but clearly prioritizes 3 half-life cessation for weight-loss patients and enhanced aspiration precautions for all high-risk scenarios.